MYGN - Myriad Genetics, Inc.
IEX Last Trade
28.32
0 0%
Share volume: 883,549
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$28.32
0.00
0.00%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-05 | 2022-11-02 | 2023-03-01 | 2023-05-04 | 2023-08-04 | 2023-11-07 | 2024-02-28 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 1.210 B | 1.212 B | 1.199 B | 1.169 B | 1.187 B | 1.149 B | 1.147 B | 1.111 B | |
| Current Assets | 367.100 M | 352.300 M | 274.600 M | 261.600 M | 294.300 M | 265.400 M | 313.600 M | 290.300 M | |
| Inventories | 15.400 M | 19.600 M | 20.100 M | 21.800 M | 22.500 M | 25.100 M | 22.000 M | 24.600 M | |
| Other Current Assets | 36.800 M | 37.300 M | 38.000 M | 42.000 M | 38.500 M | 38.800 M | 36.400 M | 43.300 M | |
| Short Term Investments | 36.800 M | 37.300 M | 38.000 M | 42.000 M | 38.500 M | 38.800 M | 36.400 M | 43.300 M | |
| Total Receivables | 109.800 M | 102.200 M | 101.600 M | 119.100 M | 111.700 M | 115.200 M | 114.300 M | 118.100 M | |
| Current Cash | 205.100 M | 193.200 M | 114.900 M | 78.700 M | 121.600 M | 86.300 M | 140.900 M | 104.300 M | |
| Total Non-current Assets | 843.100 M | 859.700 M | 924.100 M | 907.700 M | 892.900 M | 883.700 M | 832.900 M | 820.200 M | |
| Property Plant Equipment | 52.800 M | 67.500 M | 83.400 M | 96.300 M | 112.000 M | 120.700 M | 119.000 M | 118.500 M | |
| Other Assets | 8.800 M | 8.300 M | 15.500 M | 17.500 M | 22.100 M | 15.800 M | 15.400 M | 14.900 M | |
| Intangible Assets | 382.300 M | 370.800 M | 379.700 M | 369.400 M | 358.800 M | 356.600 M | 349.500 M | 340.900 M | |
| Goodwill | 237.800 M | 236.500 M | 286.800 M | 287.100 M | 287.200 M | 286.600 M | 287.400 M | 287.000 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 1.210 B | 1.212 B | 1.199 B | 1.169 B | 1.187 B | 1.149 B | 1.147 B | 1.111 B | |
| Total liabilities | 262.800 M | 295.400 M | 312.900 M | 334.100 M | 452.000 M | 465.700 M | 363.300 M | 350.500 M | |
| Total current liabilities | 119.700 M | 129.100 M | 137.200 M | 143.300 M | 221.100 M | 209.300 M | 155.900 M | 146.100 M | |
| Accounts Payable | 21.700 M | 29.600 M | 28.800 M | 36.500 M | 39.800 M | 33.900 M | 25.800 M | 33.100 M | |
| Other liabilities | 32.400 M | 32.500 M | 41.300 M | 40.200 M | 40.400 M | 70.100 M | 71.500 M | 71.400 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 38.400 M | 38.500 M | 38.500 M | 38.700 M | |
| Other liabilities | 32.400 M | 32.500 M | 41.300 M | 40.200 M | 40.400 M | 70.100 M | 71.500 M | 71.400 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 947.400 M | 916.600 M | 885.800 M | 835.200 M | 735.200 M | 683.400 M | 783.200 M | 760.000 M | |
| Common stock | 80.400 M | 80.700 M | 81.200 M | 81.300 M | 81.700 M | 81.900 M | 86.300 M | 89.900 M | |
| Retained earnings | -288.800 M | -323.900 M | -366.200 M | -420.900 M | -537.000 M | -598.300 M | -629.500 M | -655.500 M |